Related Experiment Videos
[Osteoporosis associated with inflammatory bowel diseases]
Pál Miheller1, Miklós Tóth, István Pregun
1Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest.
Orvosi Hetilap
|June 19, 2004
Summary
Inflammatory bowel diseases often cause decreased bone mineral density, a condition not solely due to treatment or malabsorption. Early diagnosis and management are crucial for preventing and treating bone loss in these patients.
Area of Science:
- Gastroenterology and Endocrinology
- Metabolic Bone Disease
- Inflammatory Bowel Disease (IBD)
Context:
- IBD, particularly Crohn's disease, is frequently associated with reduced bone mineral content (30-70%).
- Osteopenia in IBD patients is not fully explained by treatment side effects or malabsorption, suggesting a common underlying pathological pathway.
- Bone mineral density assessment via dual-ray absorptiometry at diagnosis is recommended.
Purpose:
- To highlight the prevalence and underlying causes of osteopenia in IBD.
- To outline diagnostic approaches, including routine and specialized laboratory tests.
- To present therapeutic strategies for managing metabolic bone disease in IBD.
Summary:
- Dual-ray absorptiometry is key for measuring bone mineral content at IBD diagnosis.
- Routine labs (calcium, phosphate, urinary calcium) and special tests (osteocalcin, crosslaps) aid in differential diagnosis and therapy planning.
- Calcium and vitamin D supplementation are vital. Pharmacological options include bisphosphonates, HRT, SERMs, and calcitonin for severe osteoporosis.
Impact:
- Establishes the importance of early bone density screening in IBD patients.
- Provides a framework for differential diagnosis and personalized anti-osteoporotic therapy.
- Offers a therapeutic algorithm for managing metabolic bone disease in the context of inflammatory bowel diseases.